share_log

Jefferies Financial Group Analysts Increase Earnings Estimates for Calliditas Therapeutics AB (Publ) (NASDAQ:CALT)

Defense World ·  Aug 22, 2022 02:01

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) – Research analysts at Jefferies Financial Group boosted their FY2023 earnings estimates for Calliditas Therapeutics AB (publ) in a research report issued to clients and investors on Friday, August 19th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn $4.11 per share for the year, up from their previous estimate of $3.91. The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.81) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2024 earnings at $6.74 EPS, FY2025 earnings at $8.69 EPS and FY2026 earnings at $11.10 EPS.

Get Calliditas Therapeutics AB (publ) alerts:

Several other research firms have also commented on CALT. Pareto Securities started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They set a "buy" rating for the company. Kepler Capital Markets started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They set a "buy" rating for the company. Finally, TheStreet upgraded shares of Calliditas Therapeutics AB (publ) from a "d+" rating to a "c-" rating in a research report on Thursday, August 4th.

Calliditas Therapeutics AB (publ) Stock Down 10.4 %

Calliditas Therapeutics AB (publ) stock opened at $16.13 on Monday. The company has a 50-day simple moving average of $18.77 and a 200-day simple moving average of $18.27. The firm has a market capitalization of $429.46 million, a P/E ratio of -6.48 and a beta of 1.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.36 and a current ratio of 5.37. Calliditas Therapeutics AB has a one year low of $12.55 and a one year high of $32.24.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently raised its stake in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC raised its holdings in Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after acquiring an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.10% of the company's stock.

About Calliditas Therapeutics AB (publ)

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.

Read More

  • Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
  • 2 EV Suppliers Powering To Gains After Raising Views
  • Applied Materials Results Show A Slowing Semiconductor Market
  • MarketBeat: Week in Review 8/15 – 8/19
  • Apple's Stock Could Be On The Verge Of Another 30% Rally
  • Near-Term Headwinds Present An Opportunity In Ross Stores

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment